Discovery and Identification of Potential Biomarkers in a Prospective Study of Chronic Lymphoid Malignancies Using SELDI-TOF−MS

The accurate diagnosis of the different forms of chronic mature B-cell lymphocytic malignancies is of primary importance to determine an appropriate and efficient treatment. Usually, the diagnosis is achieved by morphology and immunophenotyping. Nevertheless, the diagnostic tools available are not a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of proteome research 2006-09, Vol.5 (9), p.2258-2269
Main Authors: Miguet, Laurent, Bogumil, Ralf, Decloquement, Philippe, Herbrecht, Raoul, Potier, Noelle, Mauvieux, Laurent, Van Dorsselaer, Alain
Format: Article
Language:English
Subjects:
Amino Acid Sequence
Analytical chemistry
Biomarkers - analysis
Blood Proteins - analysis
Blood Proteins - genetics
Chemical Sciences
Chromatography, High Pressure Liquid
Electrophoresis, Polyacrylamide Gel
Lymphoma, B-Cell - blood
Lymphoma, B-Cell - diagnosis
Mass Spectrometry
Molecular Sequence Data
Protein Array Analysis
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The accurate diagnosis of the different forms of chronic mature B-cell lymphocytic malignancies is of primary importance to determine an appropriate and efficient treatment. Usually, the diagnosis is achieved by morphology and immunophenotyping. Nevertheless, the diagnostic tools available are not able to discriminate pathologies with variable evolution, or to classify some of them. To discover new biomarkers, we used peptide and protein profiling SELDI-TOF−MS, to analyze 39 chronic B-cell malignancies and 20 control serum samples. Markers of interest were subsequently identified and characterized. In the obtained SELDI−MS profiles, most of the differences were observed in three mass ranges (m/z = 13 000; m/z = 9000; m/z < 2000). Identification of these biomarkers was achieved either by direct enrichment on the ProteinChip arrays followed by on-chip-MS/MS or by chromatographic fractionation, 1D-gel followed by nanoLC−MS/MS analysis. An increase of a sulfite form of transthyretin (13 841 Da) was observed in the patient group. A second set of markers at 8.6 and 8.9 kDa was identified as complement related fragment proteins, the C3a and C4a anaphylatoxins. In the low mass range, several peptides originating from N-terminal and C-terminal processing of the C3 alpha and C4 alpha chains were specifically observed in 38% of the patient sera, but in none of the control sera. This study emphasizes the usefulness of mass spectrometry studies in such malignancies. Keywords: SELDI • biomarker • chronic B-cell lymphoid malignancy • CLL • mass spectrometry • proteomic
ISSN:1535-3893
1535-3907
DOI:10.1021/pr060058y